SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tktom who wrote (4304)6/7/2016 3:08:45 PM
From: Biomaven2 Recommendations

Recommended By
rkrw
tktom

   of 4474
 
Well the real issue that delayed the trials was the issue of early pulmonary symptoms when you start with a higher (but still relevant to ALK) dose (even 180mg). That was truly an unprecedented (in the sense that it had never been seen before with any drug) side effect and it took a while to figure out a solution. It also scared some docs (like Alice Shaw) off the drug for a long period.

Had that not happened then things would have gone much faster. So the EGFR higher-dose attempt was only a sideshow to that issue. If the issue was only encountered at say 240 mg then you would have a valid point.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News